Search Results 381-390 of 18024 for Alopecia
CTC grade 4 non-hematological Toxicity (except for alopecia, nausea, vomiting);; Significant liver function impairment - AST or ALT > 3 times the upper limit ...
*Note: Any adverse events derived from these therapies must be ≤ Grade 2 prior to starting study therapy (exception: alopecia). Participating Mayo Clinic ...
... alopecia and neuropathy - Patients who are receiving any other investigational agents - History of allergic reactions attributed to compounds of similar ...
... alopecia, peripheral neuropathy and ongoing endocrinopathies controlled on appropriate replacement therapy * Have significant cardiovascular disease defined ...
Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy; with the exception of vitiligo and alopecia. Participating Mayo Clinic ...
... alopecia and other non-clinically significant adverse events (AEs); Patients with no known brain metastasis at baseline must have baseline brain imaging ...
... alopecia and the criteria outlined; Patients must not have any history of cancer within 5 years from randomization, with the exception of in-situ carcinomas ...
... alopecia in breast cancer patients. Support Care Cancer. 2023 Nov 22; 31 (12):717. View PubMed; Cathcart-Rake EJ, Tevaarwerk AJ, Haddad TC, D'Andre SD, Ruddy ...
Alendronate and cholecalciferol combination is used to treat osteoporosis (thinning of the bone) in women after menopause. This medicine may also be used to ...
* Lupus headache, alopecia, organic brain syndrome, and mucosal ulcers must be recorded on SLEDAI 2K, if indicated, but do not count toward the points ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.